SAN DIEGO--(BUSINESS WIRE)--Polynoma, Inc., an oncology-focused biotechnology company within Hong Kong-based CK Life Sciences Int’l., (Holdings) Inc., today announced the appointment of John Chiplin, Ph.D., to the newly established position of Chief Executive Officer. Dr. Chiplin brings over 25 years of biopharmaceutical and healthcare-related experience to Polynoma.
Dr. Chiplin has broad-based experience in the life science and technology industries, both from an operational and investment perspective. Most recently, he was founding CEO of Arana Therapeutics, a new generation antibody developer and a board member of Domantis, Inc., prior to the acquisition of these companies by Cephalon and GSK, respectively. Prior to running Arana, he was head of the ITI Life Sciences investment fund in the UK. Dr. Chiplin holds Pharmacy and Doctoral degrees from the University of Nottingham, UK.
“I am privileged to join Polynoma at this transformative moment in the Company’s development,” commented Dr. Chiplin. “The core of Polynoma’s approach is a novel shed antigen vaccine technology that I believe can have broad applications in oncology. Our focus is on the Company’s recently announced Phase 3 clinical program in melanoma, an area of substantial unmet need. I look forward to additional progress in advancing this program and in announcing further expansion of the organization’s senior leadership team and advisors.”
Recently, Polynoma reported the initiation of its Phase 3 clinical trial program for POL 103A, the Company’s novel melanoma vaccine. Polynoma’s global, multi-center, double-blind, placebo-controlled Melanoma Antigen Vaccine Immunotherapy Study (MAVIS) is designed to enroll a total of 1059 patients with resected Stage IIb, IIc or III melanoma. The trial is being conducted under a Special Protocol Assessment (SPA) agreed upon with the U.S. Food and Drug Administration (FDA).
About Polynoma
Polynoma, Inc. is an oncology-focused biotechnology company based in San Diego, the United States of America. Polynoma’s lead product candidate is the therapeutic vaccine POL 103A for the treatment of melanoma. The Phase 3 trial of POL 103A was initiated based on two randomized, controlled Phase 2 trials that showed statistically significant efficacy and safety data. In addition to melanoma, Polynoma is also planning to evaluate the effectiveness of the vaccine in other cancer indications. For additional information, please visit www.polynoma.com.
About CK Life Sciences
CK Life Sciences Int'l., (Holdings) Inc. is a listed company on The Stock Exchange of Hong Kong Limited (stock code: 0775). Bearing the mission of improving the quality of life, the Company is engaged in the business of research and development, commercialisation, marketing and sale of health and agriculture related products. CK Life Sciences is a member of the Cheung Kong Group. For additional information, please visit www.ck-lifesciences.com.